The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Oceania Healthcare’s (OCA) Chief Executive, Earl Gasparich, has resigned from his role with the company
  • Earl held the position for seven years, during which time he oversaw the company’s listing on the ASX
  • Gasparich will succeed Glen Sowry as CEO of Metlifecare, following an announcement from the company today   
  • The Oceania Board has appointed Chief Financial Officer Brent Pattison as Acting Chief Executive Officer, effective immediately
  • Oceania is down 2.26 per cent, trading at $1.30

Oceania Healthcare’s (OCA) Chief Executive, Earl Gasparich, has resigned from his role with the company.

Oceania Healthcare is a leading provider of healthcare services in New Zealand.

The outgoing CEO first joined Oceania in August 2014 and led the company through a period of growth and transformation, including its initial public offering in May 2017 and the challenges of COVID-19.

Outside of his work at Oceania Healthcare, Gasparich also volunteers on the Boards of a number of charities involved in the provision of community services.

The Oceania Board has appointed Brent Pattison, Oceania Healthcare Chief Financial Officer, to the role of Acting Chief Executive Officer, effective immediately.

“The Board extend our gratitude and thanks to Earl for his contribution over his six and a half years with us,” said Oceania Chair Liz Coutts.

The company says they are now well positioned for growth in the years ahead.

Earl Gasparich will go on to succeed Glen Sowry as CEO of New Zealand-based retirement village provider Metlifecare.

“Earl knows the sector well and we are highly confident that he brings the skill and experience needed to deliver the ongoing leadership and capability to progress Metlifecare’s growth strategy,” said Metlifecare Chair, Paul McClintock.

Sowry will leave Metlifecare on March 31, and Gasparich is expected to commence at Metlifecare in the middle of the year.

Oceania is down 2.26 per cent, trading at $1.30 at 4:00 pm AEDT.

oca by the numbers
More From The Market Online

LTR Pharma’s SPONTAN investigation in pulmonary arterial hypertension approved

LTR Pharma has received approval for an investigator-initiated clinical study evaluating SPONTAN in patients with newly…

Pro Medicus signs $43M, seven-year contract with Virtua Health in US

Pro Medicus' wholly-owned US subsidiary, Visage Imaging, has signed a seven-year, $43 million contract with Virtua…

Recce welcomes positive phase 3 clinical trial data for topical gel for diabetic foot ulcer infections

Recce Pharmaceuticals has reported a review of blinded data of its current phase 3 trial has…
Blood sample blood test blood concept

Newest ASX listee Identifai Genetics up +20% on IPO day eyeing prenatal screening disruption in the USA

The newest company to hit the ASX, Identifai Genetics (ASX:ID1), has seen its shares jump +20% on some...